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ABSTRACT 
 
Objective: The objective of this EBM review is to determine whether or not “Is oral aloe vera 
effective in reducing symptoms in adults with Irritable Bowel Syndrome (IBS) symptoms?”  
 
Study Design: Systematic review of three English, randomized, controlled, double-blind studies, 
including one cross-over study, were selected based on their relevance to the clinical question. 
The studies were published in 2006, 2011, and 2015. 
 
Data Sources: Three RCTs analyzing the effects on IBS symptoms of drinking aloe vera daily 
compared to a placebo drink were found using PubMed. 
 
Outcomes Measured: Various patient-reported IBS symptom questionnaires were utilized to 
compare the effectiveness of drinking oral aloe vera versus the placebo on reducing symptoms in 
adults with irritable bowel syndrome (IBS). K. Davis used the Global Summated Symptom 
Score.2 Storsrud S. used the IBS Symptom Severity Scoring System (IBS-SSS).4 H.A. Hutchings 
used the Irritable Bowel Syndrome Quality of Life Questionnaire (IBSQOL).3  
 
Results: In the Davis et al study, there was no significant improvement of IBS symptoms 
between the aloe vera and placebo group (p= 0.12). The NNT was -11.2 In the Storsrud et al pilot 
study, there was no significant improvement in IBS symptoms in using the Aloe barbadensis 
Mill. extract in comparison to the placebo (p=0.09). The NNT was 5.4 In the Hutchings et al 
study, there was no significant improvement of IBS symptoms between the aloe vera and 
placebo group (p>0.05). The mean change from baseline was 69-74 points on the ISBQOL score 
for period 1.3 
 
Conclusions: Although two of the studies showed trends towards improvement, all three studies 
were not considered statistically significant in showing improvement in symptoms in IBS 
symptoms. Therefore, oral aloe vera is not considered effective in reducing symptoms in adults 
with irritable bowel syndrome. Additionally, after my further research via WebMD on the safety 
of drinking aloe vera, I found varying results for whom it was considered safe. I would suggest 
that future studies first assess its safety before evaluating it effectiveness in reducing IBS 
symptoms.  
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Introduction 
Irritable bowel syndrome (IBS) largely affects the United States in population and cost. IBS 
is characterized by a collection of symptoms such as cramping, abdominal pain, bloating, 
diarrhea, and constipation for at least three months.5 The condition does not permanently harm 
the large intestine, nor lead to serious disease like cancer. However, the frustrating symptoms 
may hinder the patient’s quality of life, such as in traveling and working. Because no definitive 
cure exists, patients and providers are often searching for additional natural remedies for patients 
to try at home. This systemic review evaluates three double-blind, randomized, controlled trials, 
including a cross-over study, assessing the effectiveness of drinking aloe vera on symptomtic 
improvement in adults with IBS. 
Up to 20 percent of U.S. adults suffer with IBS symptoms, making it one of the most 
common disorders diagnosed by doctors.5 Women, individuals younger than 50 (usually 
beginning before age 35) and people with a family member who has IBS are most likely to 
develop IBS.5 The total direct cost related to IBS was $1.35 billion dollars and $619 per patient.4 
IBS accounts for 3.5 million physician visits per year, accounting for 25% of all GI visits. 
Furthermore, only 10-25% of symptomatic patients seek medical care.4  
The cause of IBS is not well understood and there is no cure. Although numerous treatments 
for IBS exist, each patient responds differently, and many still suffer with the frustrating IBS 
symptoms. Some physicians recommend diet alterations such as 4-5 smaller meals/day, high 
fiber meals, and 6-8 glasses of water/ day.5 Physicians may also recommend medications such as 
fiber supplements, anti-diarrheal medications such as loperimide, antispasmodic agents such as 
dicyclomine or peppermint oil, antidepressants such as TCAs or SSRIs, or IBS medications such 
as Lubiprostone.5 Cognitive and stress relief therapy are also often supplemental suggestions. 
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These include CBT, psychotherapy, and hypnotherapy.5 Although several treatment options exist 
for patients with IBS, many patients are still searching for an effective option that is natural and 
easily maintainable.  
 
Objective 
The objective of this selective EBM review is to determine whether or not “Is oral aloe vera 
effective in reducing symptoms in adults with irritable bowel syndrome (IBS)?”  
 
Methods 
The criteria used for the selection of studies included the population, intervention, 
comparison, outcomes, and study type. The population consisted of individuals >18 y.o. with 
IBS according to Rome II or III criteria. The interventions included drinking aloe vera solutions 
of 50 ml QID, 60 ml BID, or 250 mg of AVH200 dissolved in water BID. The comparisons 
included drinking the placebo solution of 50 ml QID, 60 ml BID or 50 ml QID, or 60 mg tablets 
of ascorbic acid and excipients dissolved in water BID. The outcomes were evaluated via 
patient-reported questionnaires assessing the improvement of IBS symptoms with the use of 
daily aloe vera. The studies chosen were 3 randomized, double-blind, placebo controlled clinical 
trials, one of which being a cross-over study. The studies were published in 2006, 2011, and 
2015.2,3,4 See Table 1 for demographics of each study. 
The data were collected by searching the key words aloe vera and IBS on English, peer-
reviewed journals via PubMed. Articles were selected based on their relevance to the clinical 
question and that the study outcomes were patient oriented (POEMS). Inclusion criteria included 
studies that were randomized, double-blind, and controlled including adults >18 y.o. who were 
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diagnosed with IBS. Exclusion criteria excluded studies performed before 2001 or previous 
Cochrane systemic reviews on my topic. The statistics reported were numbers needed to treat 
(NNT), relative benefit increase (RBI), absolute benefit increase (ABI), mean change from 
baseline, and p-values.  
Table 1: Demographics and Characteristics of Included Studies 
Study Type # 
Patients 
Age 
(years) 
Inclusion  
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Davis2 Double-
blind 
RTC 
54 18-65 Adults 18-65y.o. 
who satisfy the 
Rome II criteria 
who had 
previously tried 
and failed 
conventional 
management 
On 
medications 
other than 
related to 
IBS, other 
medical 
conditions, 
pregnant 
1mo
-9 
3mo
-8 
Aloe vera 
(50 ml QID 
for 3 months) 
Hutchings3 Double-
blind 
RTC 
(Cross 
over) 
110 >18 Adults >18y.o. 
diagnosed with 
IBS according to 
the Rome II 
criteria for > 1 
year and had 
received previous 
treatment; c/o 
abdominal pain, 
seeking further 
treatment; willing 
and able to give 
consent to be 
randomized in 
the study; 
females with a 
negative 
pregnancy test 
Significant 
GI tract 
disease, had 
undergone 
previous GI 
surgery, 
were known 
defaulters at 
clinic and 
might be 
difficult to 
follow up, 
were on 
drugs that 
might affect 
motility, or 
had a current 
or recent Hx 
of drug or 
alcohol 
abuse 
63 Aloe vera 
(60 mg BID 
for 5 months, 
2 week wash 
out period, 5 
months alt. tx 
Storsrud4 Double-
blind 
RTC 
68 18-65  Adults ages 18-
65y.o. with IBS 
according to the 
Rome III criteria, 
and were 
Other GI dz 
explaining 
the sxs, food 
allergy or 
intolerance 
5 Aloe 
barbadenses 
Mill. Extract 
(250 mg in 
water BID, 
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evaluated by a 
gastroenterologist 
other than 
lactose 
intolerance, 
other severe 
disease, sxs 
indicating 
other severe 
dz 
before 
breakfast and 
late in the 
evening for 4 
weeks 
 
 
Outcomes measured 
Various patient-reported IBS symptom questionnaires were utilized to compare the 
effectiveness of drinking oral aloe vera daily versus the placebo on reducing symptoms in adults 
with irritable bowel syndrome (IBS). K. Davis used the Global Summated Symptom Score for 
abdominal pain, distension, satisfaction with bowel habit, and global impact of symptoms on 
well-being. A reduction of ≥ 50 points qualified as improvement. S. Storsrud used the IBS 
Symptom Severity Scoring System (IBS-SSS), which assesses pain severity, pain frequency, 
bloating severity, bowel habit dissatisfaction, and life interference. An improvement was defined 
as a reduction of ≥ 50 points on the IBS-SSS questionnaire.  H.A. Hutchings used continuous 
data from the Irritable Bowel Syndrome Quality of Life Questionnaire (IBSQOL) involving 8 
subscales: emotional health, mental health, sleep, energy, physical functioning, diet, social role, 
and physical role.  
 
Results 
Three double-blind, placebo controlled RTCs were used to determine whether drinking 
aloe vera improves symptoms in adults with IBS. In the Davis et al study, there was no 
significant improvement of IBS symptoms between the aloe vera and placebo group (p= 0.12). 
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For this study, 54 subjects were either randomized to receive 50 ml QID of an aloe vera solution 
or the 50 ml of placebo solution for 3 months.  Patients were selected from gastroenterology 
clinics from two large hospitals in London and were allocated their medication through the 
central pharmacy of each hospital. Both the experimental and placebo solutions were pink syrup 
flavored with mango. Inclusion criteria included patients who had IBS according to the Rome II 
criteria, aged 18-65, and had previously tried but failed conventional management with 
antispasmodics, bulking agents, and dietary intervention. Exclusion criteria for this study 
excluded patients who were on medications other than those related to IBS, had other medical 
conditions, including those related to the bowel, or were pregnant or at risk of pregnancy.2 
All of the patients, researchers, and doctors remained blind throughout the study. The 
data were presented at dichotomous data, and at the end of three months, the response by 
intention to treat was 5 of 18 (28%) and 5 of 26 (18%) in the placebo and active group 
respectively. At the conclusion of the study, 13 out of 54 subjects (24%) were lost to follow-up. 
Six patients withdrew due to nausea and vomiting. The outcome was measured by change in 
global summated symptom score and global impact of symptoms on well-being; a reduction of ≥ 
50 points qualified as improvement. The experimental group was then compared to the placebo 
group results. The NNT was -11. Therefore, for every 11 patients treated with oral aloe vera, one 
less would show improvement in comparison to the placebo treatment.2 The RBI was -0.32 and 
the ABI was -0.09. The results for calculations of efficacy may be found in Table 2.  
In the Storsrud et al pilot study, there was no significant improvement in IBS symptoms 
in using the Aloe barbadensis Mill. extract in comparison to the placebo (p=0.09). For this study, 
patients were selected from referrals to gastroenterology outpatient clinic as well as from 
advertisements in local newspapers. Inclusion criteria included adult patients (18-65y.o.) who 
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had signed a written informed consent, had IBS according to the Rome III criteria, were 
evaluated by a gastroenterologist, and have the ability to understand and willingness to comply 
to the study procedures. Exclusion criteria excluded those with other gastrointestinal disease(s) 
explaining the symptoms, food allergy or intolerance other than lactose intolerance, other severe 
disease(s) such as malignancy, severe heart disease, kidney disease neurological disease, 
symptoms indicating other severe disease(s) such as weight loss, gastrointestinal bleeding or 
fever, or severe psychiatric disease. Patients who were already using of aloe vera products or 
were pregnant or lactating were also excluded. Sixty-eight patients were eligible and 33 were 
randomized to receive Aloe barbadenses Mill. extract in water (250 mg AVH200®, 60 mg 
ascorbic acid and excipients) and 35 to the matching placebo BID, before breakfast and late in 
the evening, for 4 weeks. Patients completed weekly questionnaires to assess IBS symptom 
severity.4 
Researchers, doctors, and patients were kept blind throughout the study, and the data 
were presented as dichotomous data. At the end of 4 weeks, the response by intention-to-treat 
was assessed with drop-outs counted as non-responders and missing data imputed from the 
previous assessment using the last observation carried forward technique, and was all included in 
the analysis. At the conclusion of the study, 55% of the aloe vera group and 31% of the placebo 
group qualified as an improvement in symptoms, and 5 subjects were lost to follow-up.  
Improvement was defined by a reduction of ≥50 points on the IBS-SSS questionnaire after 4 
weeks. A follow-up symptom questionnaire via a telephone was additionally administered 2 
weeks after the conclusion of the treatment period. The results of the experimental group were 
compared to the placebo group. NNT was calculated as 5, meaning for every 5 subjects treated 
with aloe vera, one patient would statistically improve as compared to the placebo treatment. The 
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RBI was 0.77 and the ABI was 0.24.4 Results for calculations of efficacy may be found in Table 
2. 
Table 2 
 RBI ABI NNT p-value 
Davis et al2 -0.32 -0.09 -11 0.12 
Storsrud et al4 0.77 0.24 5 0.09 
 
In the Hutchings et al study, there was no significant improvement of IBS symptoms 
between the aloe vera and placebo group (p>0.05). This study was a multi-centre prospective 
randomized, double-blind, cross-over study of 110 subjects. Inclusion criteria included those 
who were at least 18 years, diagnosed as suffering with IBS according to the ROME II Criteria 
for at least one year and had received precious treatment, complaining of abdominal pain and 
were seeking further treatment. The subjects must have been able and willing to give consent to 
be randomized into the study. Females patients were included if they were taking adequate 
contraceptive precautions and had a negative pregnancy test at baseline, patients on medication 
for stable medical conditions not considered to yield an effect on the study were eligible for 
recruitment, and specific medications for diarrhea or constipation were permitted. Exclusion 
criteria excluded those who had other significant GI tract disease, had undergone previous GI 
tract surgery, were known to be defaulters at clinic and might be difficult to follow up, were on 
drugs which might affect motility, or had a current of recent history of drug or alcohol abuse. 
Qualifying subjects in 3 hospitals in South West Whales, UK were randomized into groups of 55 
patients to drink a 60 ml of aloe vera drink twice a day (Group AB) or a matching placebo drink 
twice a day (Group BA). Group AB drank the aloe vera for 5 months, had a 2-week “wash out” 
period, and continued with another 5 months with the placebo, while group BA began with the 
placebo and and ended with the aloe vera for period 1.3  
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The researchers, doctors, and patients were kept blind throughout the study, and the data 
were continuous and not convertible to dichotomous data. The subjects were analyzed based on 
“intention to treat,” and improvement was assessed using The Irritable Bowel Syndrome Quality 
of Life Questionnaire (IBSQOL) at baseline, at the end of study period 1 (5 months), and at the 
end of study 2 (10 months).3 The mean change from baseline was 69-74 points on the ISBQOL 
score for period 1. Independent sample T-tests or chi-square were also used to assess baseline 
differences in the groups before the study. By the end of the 10 months, only 47 out of the 110 
(43%) finished the entire study, and 63 subjects (57%) were lost to follow-up.3 Results for 
calculations of efficacy may be found in Table 3.  
Table 3 
 Mean change from baseline at 
the end of period 1 using the 
IBSQOL 
p-value 
Hutchings et al3 69-74 > 0.05 
 
Discussion 
In the Davis et al study, there was no evidence that drinking aloe vera daily benefits 
patients with IBS (p= 0.12). Nausea and vomiting with drinking the solution may have affected 
the outcome. However, the majority of the nausea and vomiting came from the placebo group 
and therefore, was not considered to be a significant side effect. According to the Davis et al 
study, the results were unable to rule out the possibility that improvement occurred in patients 
with diarrhea or alternating IBS while taking aloe vera (AV). Therefore, authors of the study 
suggested that further investigations be warranted in patients with diarrhea predominant IBS.2  
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In the Storsrud et al study, several limitations may have affected this study. First of all, 
this was a pilot study which was aimed to find tendencies towards group differences to detect 
potentially clinically meaningful differences, and to plan future studies based on the findings.4 
Now, a larger study is claimed to be proceeding with a sample size based on the observed effect 
size in this study.4 Additionally, although the groups were randomized, the aloe vera group had a 
tendency towards higher severity of IBS symptoms at baseline, and some of the results could 
possibly be due to regression towards the mean. However, when using the adequate relief 
endpoint, a trend defined as improvement IBS-SSS reduction was noted. The ongoing larger 
study should help these limitations be overcome.4   
In the Hutchings et al study, although both study groups were entirely compliant with the 
allocated treatments and all treatment containers were returned empty, poor recruitment 
numbers, a large number of patients withdrawing from the study, and the long treatment period 
all may have had an effect on the results. Moreover, only about 10% of over 1000 patients 
initially identified with symptoms suggestive of IBS were recruited, which could indicate that the 
sample was not truly representative of the wide spectrum of IBS patients. Additionally, the 
requirement to discontinue certain medications prior to entering the study may have further 
impacted those recruited.3 
The combination of decreased recruitment rate and the number of drop-outs throughout 
the study reduced the power of the study. Patients discontinued the study for a variety of reasons 
including an increase in symptoms, which was noted more markedly in the Aloe vera group.3  
Aloe is a cactus-like plant found in the United States growing in hot, dry environments 
and comes in two forms, gel and latex. Although not proven to be effective in many cases, aloe 
vera may be taken by mouth or applied topically to the skin for a vast variety of conditions. 
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According to WebMD, topical application of aloe vera may possibly be an effective treatment 
for acne, burns, genital herpes, pruritic rashes, oral submucous fibrosis, and psoriasis.1 Ingestion 
of aloe vera may possibly be effective for weight loss and constipation.1 It is important to note, 
however, that the U.S Food and Drug administration does not precisely regulate herbs and 
supplements, so there is no guarantee of the strength, purity, and safety of aloe vera. According 
to an overview in WedMD, applying aloe vera gel topically is “likely safe.”1 However, ingesting 
aloe vera is “possibly safe” when taken short term.1 Furthermore, ingesting aloe latex long-term 
is “possible unsafe” at any dose, but “likely unsafe” in high doses.1 Side effects may cause 
stomach pain and cramps, and long-term use of large amounts of aloe latex could cause diarrhea, 
kidney problems, blood in the urine, low potassium, muscle weakness, weight loss, and heart 
disturbances.1 Taking aloe latex 1 gram daily for several days can be fatal.1 People who are 
pregnant, or have diabetes, intestinal conditions such as Crohn's disease, ulcerative colitis, or 
obstruction, hemorrhoids, kidney issues, or recent surgery should avoid use of aloe vera. Also, 
aloe vera has a major negative drug interaction with digoxin and should be avoided.1  
 
Conclusion 
All three studies were not considered statistically significant in showing symptomatic 
improvement in adults with IBS. The Storsrud et al study was the only study to show a trend 
towards improvement of IBS symptoms. Therefore, oral aloe vera is not considered effective in 
reducing symptoms in adults with irritable bowel syndrome.  
Additionally, after my further research via WebMD on the safety of drinking aloe vera, I 
found varying results for whom it was considered safe. I would suggest that future studies first 
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assess the safety of ingesting the aloe vera. Then, once statistically determined, supplemental 
studies could assess its effectiveness in reducing IBS symptoms.   
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